Immune Thrombocytopenic Purpura (ITP) Treatment Guidelines

First-Line Treatment

The American Society of Hematology recommends initiating corticosteroids as first-line therapy for newly diagnosed adult ITP, specifically prednisone 0.5-2 mg/kg/day or high-dose dexamethasone 40 mg/day for 4 days, and adding intravenous immunoglobulin (IVIg 1 g/kg) only when rapid platelet elevation is needed for active bleeding or urgent procedures 1, 2
Treatment decisions should prioritize bleeding symptoms over absolute platelet counts, with treatment indicated when platelet counts are <20-30 × 10⁹/L, as bleeding risks significantly increase below this threshold 1, 2
The goal is maintaining a hemostatic platelet count (typically 30-50 × 10⁹/L), not normalizing counts, with the American College of Physicians recommending against prolonged corticosteroid therapy beyond 4-6 weeks in non-responders 2, 3

The American Society of Hematology recommends thrombopoietin receptor agonists (TPO-RAs) as the preferred second-line therapy for long-term management of ITP, with romiplostim and eltrombopag being effective options 2, 3
Splenectomy provides long-term responses but should be delayed given the availability of TPO-RAs, with an initial response rate of 80-85% and long-term durable response of 60-70% of patients maintaining response over 4 years 4, 2, 3
Rituximab is an alternative second-line option, with response rates of 31-79% overall and 40% achieving complete response, and long-term sustained responses of 20-30% of cases 4, 2, 3

In children with ITP, the goal is maintaining hemostatic platelet counts while minimizing prolonged corticosteroid use, with first-line treatment options including IVIg, IV anti-D, or short-course corticosteroids, and high-dose methylprednisolone being at least as effective as IVIg 4, 2, 3
In pregnancy, corticosteroids or IVIg should be used as first-line therapy, with the mode of delivery based on obstetric indications, not platelet count 2
In secondary ITP, treatment of the underlying condition is recommended, with HCV-associated ITP considering antiviral therapy and HIV-associated ITP treating HIV with antivirals before other ITP therapy unless significant bleeding 2

Minimize bleeding risk through non-pharmacologic interventions, including discontinuing antiplatelet agents unless absolutely necessary, controlling blood pressure aggressively, suppressing menses in menstruating patients, and considering higher target platelet counts for patients with cardiac stents requiring antiplatelet therapy 2